Literature DB >> 22734597

Outcome of children with refractory anaemia with excess of blast (RAEB) and RAEB in transformation (RAEB-T) in the Japanese MDS99 study.

Akira Kikuchi1, Daisuke Hasegawa, Yoshitoshi Ohtsuka, Kazuko Hamamoto, Seiji Kojima, Jun Okamura, Tatsutoshi Nakahata, Atsushi Manabe.   

Abstract

We report the outcome of 16 children with refractory anaemia with excess of blasts (RAEB; n = 4) and RAEB in transformation (RAEB-T; n = 12) following induction therapy with etoposide, cytarabine and mitoxantrone (ECM) prior to haematopoietic stem cell transplantation (HSCT). The median observation period was 77 months (range 5-123). Complete remission rate was 81% following induction; no toxic deaths occurred. Eight-year event-free survival and overall survival was 50% and 56%, respectively. None of the three patients with a complex karyotype survived, suggesting karyotype is a crucial prognostic factor for survival. This study indicates the safety and high remission rate of ECM and high survival rates after HSCT for paediatric RAEB and RAEB-T.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22734597     DOI: 10.1111/j.1365-2141.2012.09210.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

1.  Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006-2010): based on registry data from the Japanese Society of Pediatric Hematology.

Authors:  Keizo Horibe; Akiko M Saito; Tetsuya Takimoto; Masahiro Tsuchida; Atsushi Manabe; Midori Shima; Akira Ohara; Shuki Mizutani
Journal:  Int J Hematol       Date:  2013-05-24       Impact factor: 2.490

2.  A Computational Framework for Genome-wide Characterization of the Human Disease Landscape.

Authors:  Young-Suk Lee; Arjun Krishnan; Rose Oughtred; Jennifer Rust; Christie S Chang; Joseph Ryu; Vessela N Kristensen; Kara Dolinski; Chandra L Theesfeld; Olga G Troyanskaya
Journal:  Cell Syst       Date:  2019-01-23       Impact factor: 10.304

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.